Northrop Grumman (NOC) Shareholder Chilton Capital Management Has Upped Position; Sector Gamma As Holding in Clovis Oncology (CLVS) Has Raised by $338,865

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Sector Gamma As increased its stake in Clovis Oncology Inc (CLVS) by 6.72% based on its latest 2018Q3 regulatory filing with the SEC. Sector Gamma As bought 11,685 shares as the company’s stock declined 38.46% with the market. The institutional investor held 185,577 shares of the health care company at the end of 2018Q3, valued at $5.45M, up from 173,892 at the end of the previous reported quarter. Sector Gamma As who had been investing in Clovis Oncology Inc for a number of months, seems to be bullish on the $1.34B market cap company. The stock increased 0.87% or $0.22 during the last trading session, reaching $25.41. About 622,864 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 63.47% since February 13, 2018 and is downtrending. It has underperformed by 63.47% the S&P500. Some Historical CLVS News: 08/05/2018 – Clovis Oncology 1Q Loss $77.7M; 23/03/2018 – CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca Tablets; 10/04/2018 – CLOVIS ONCOLOGY: SEC WANTS ADDED CLINICAL DATA ON ROCILETINIB; 03/04/2018 – AstraZeneca PLC European Medicines Validated for Review Application for Lynparza; 16/05/2018 – G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; 16/05/2018 – Clovis Oncology at Bank of America Conference Tomorrow; 10/04/2018 – CLOVIS ONCOLOGY – SEC’S ‘WELLS NOTICES’ ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934; 08/05/2018 – CLOVIS ONCOLOGY INC CLVS.O : RBC RAISES TARGET PRICE TO $74 FROM $73; 06/04/2018 – CLOVIS ONCOLOGY-IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL; 08/05/2018 – Merck: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer

Chilton Capital Management Llc increased its stake in Northrop Grumman Corp (NOC) by 20.24% based on its latest 2018Q3 regulatory filing with the SEC. Chilton Capital Management Llc bought 5,757 shares as the company’s stock declined 11.09% with the market. The institutional investor held 34,196 shares of the industrial machinery and components company at the end of 2018Q3, valued at $10.85 million, up from 28,439 at the end of the previous reported quarter. Chilton Capital Management Llc who had been investing in Northrop Grumman Corp for a number of months, seems to be bullish on the $48.21B market cap company. The stock decreased 0.01% or $0.03 during the last trading session, reaching $284.05. About 211,592 shares traded. Northrop Grumman Corporation (NYSE:NOC) has declined 10.72% since February 13, 2018 and is downtrending. It has underperformed by 10.72% the S&P500. Some Historical NOC News: 25/04/2018 – Northrop Grumman Beats Profit And Sales Expectations, Raises Outlook — MarketWatch; 30/03/2018 – Northrop Grumman: Victor H. Fazio to Retire From Board; 08/04/2018 – Probes Point to Northrop Grumman Errors in January Spy-Satellite Failure; 30/03/2018 – Northrop Grumman Revises Satellite Procedures After Telescope Delay; 15/05/2018 – Northrop Grumman Raises Dividend to $1.20; 05/04/2018 – U.S. State Dept OKs possible $2.5 bln sale of military drones to Germany; 25/04/2018 – NORTHROP GRUMMAN BOOSTS FORECAST; 25/04/2018 – Northrop Grumman Still Sees 2018 Operating Margin About 12%; 28/03/2018 – Poland Signs Agreement to Purchase Northrop Grumman’s Integrated Air and Missile Defense Battle Command System; 19/04/2018 – DJ Northrop Grumman Corporation, Inst Holders, 1Q 2018 (NOC)

Since December 4, 2018, it had 0 buys, and 5 selling transactions for $60,638 activity. 250 shares valued at $5,308 were sold by IVERS-READ GILLIAN C on Tuesday, December 4. $3,991 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) was sold by MUEHL DANIEL W on Tuesday, December 4.

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Seekingalpha.com which released: “Clovis Oncology: Outlook Post-Tesaro Acquisition – Seeking Alpha” on December 06, 2018, also Nasdaq.com with their article: “Clovis’ (CLVS) Rubraca Gets Another US Patent, Shares Up – Nasdaq” published on November 21, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare – Seeking Alpha” on October 19, 2018. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: Seekingalpha.com and their article: “Clovis Oncology announces second U.S. patent issued in Rucaparib high dosage strength tablet – Seeking Alpha” published on November 20, 2018 as well as Seekingalpha.com‘s news article titled: “Clovis: When All Rush To Exit – Seeking Alpha” with publication date: October 25, 2018.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 68 analyst reports since September 10, 2015 according to SRatingsIntel. Oppenheimer initiated the stock with “Hold” rating in Friday, March 23 report. The company was maintained on Wednesday, November 15 by Leerink Swann. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. The firm earned “Buy” rating on Wednesday, September 6 by J.P. Morgan. Chardan Capital Markets downgraded the shares of CLVS in report on Friday, February 3 to “Sell” rating. Chardan Capital Markets upgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, June 19 to “Neutral” rating. The rating was maintained by Credit Suisse on Tuesday, July 18 with “Buy”. The rating was maintained by Leerink Swann with “Buy” on Monday, July 31. The rating was upgraded by Credit Suisse on Wednesday, September 21 to “Outperform”. As per Friday, August 5, the company rating was initiated by Suntrust Robinson.

Investors sentiment decreased to 1.14 in 2018 Q3. Its down 0.03, from 1.17 in 2018Q2. It turned negative, as 30 investors sold CLVS shares while 47 reduced holdings. 29 funds opened positions while 59 raised stakes. 53.65 million shares or 1.55% more from 52.83 million shares in 2018Q2 were reported. California State Teachers Retirement Systems reported 72,843 shares. Price T Rowe Md accumulated 181,088 shares or 0% of the stock. Aqr Mgmt Limited Liability Com invested 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Kbc Gp Nv has 241,729 shares. Jabre Capital Prns Sa holds 0.29% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 30,000 shares. 82,430 are owned by Opus Point Ptnrs Mngmt Lc. Ny State Common Retirement Fund invested in 53,000 shares. Sei Investments Com holds 19 shares. Stifel stated it has 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). California Employees Retirement System accumulated 65,400 shares. San Francisco Sentry (Ca) has 400 shares for 0% of their portfolio. Prelude Capital Management Ltd Co reported 0.03% stake. Deutsche Fincl Bank Ag stated it has 211,720 shares. D E Shaw Company holds 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 236,950 shares. Fisher Asset Management Limited Liability invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS).

Sector Gamma As, which manages about $637.80M US Long portfolio, decreased its stake in Merck & Co Inc (NYSE:MRK) by 182,784 shares to 731,046 shares, valued at $51.86 million in 2018Q3, according to the filing. It also reduced its holding in Lilly Eli & Co (NYSE:LLY) by 167,991 shares in the quarter, leaving it with 13,650 shares, and cut its stake in Baxter Intl Inc (NYSE:BAX).

Investors sentiment decreased to 0.97 in Q3 2018. Its down 0.04, from 1.01 in 2018Q2. It worsened, as 62 investors sold NOC shares while 271 reduced holdings. 95 funds opened positions while 228 raised stakes. 139.01 million shares or 1.40% more from 137.09 million shares in 2018Q2 were reported. Canal reported 40,093 shares. Mirae Asset Global holds 0.03% of its portfolio in Northrop Grumman Corporation (NYSE:NOC) for 12,546 shares. Telemus Cap Limited Company has 6,049 shares for 0.14% of their portfolio. Bluestein R H And holds 2.01% or 131,407 shares in its portfolio. Horrell Capital Mngmt holds 0% or 27 shares in its portfolio. 19,378 were reported by Hartford Inv Management Communications. Alpha Windward Limited Liability Corp has invested 0.19% in Northrop Grumman Corporation (NYSE:NOC). Linscomb And Williams Inc holds 0.03% or 1,010 shares in its portfolio. Westwood Hldgs Gp Inc reported 247,776 shares or 0.69% of all its holdings. Boston Advsrs Lc has 0.18% invested in Northrop Grumman Corporation (NYSE:NOC) for 12,897 shares. Pittenger & Anderson Inc holds 450 shares. Daiwa Secs Group Inc reported 6,449 shares. Virginia-based Heritage Wealth Advsr has invested 0% in Northrop Grumman Corporation (NYSE:NOC). Texas Permanent School Fund invested in 0.17% or 39,088 shares. Haverford Tru Co reported 5,750 shares.

More notable recent Northrop Grumman Corporation (NYSE:NOC) news were published by: Globenewswire.com which released: “Northrop Grumman Announces Change in Pension Accounting – GlobeNewswire” on December 10, 2018, also Finance.Yahoo.com with their article: “Should You Be Holding Northrop Grumman Corporation (NYSE:NOC)? – Yahoo News” published on November 17, 2018, Benzinga.com published: “Credit Suisse Expects Northrop Grumman To Outperform (NYSE:NOC) – Benzinga” on January 14, 2019. More interesting news about Northrop Grumman Corporation (NYSE:NOC) were released by: Seekingalpha.com and their article: “Northrop Grumman: Price Is Lower Despite Less Risks – Seeking Alpha” published on December 15, 2018 as well as Bizjournals.com‘s news article titled: “Marriott and Nestle make Fortune’s most admired list – Washington – Washington Business Journal” with publication date: January 23, 2019.

Among 23 analysts covering Northrop Grumman (NYSE:NOC), 16 have Buy rating, 0 Sell and 7 Hold. Therefore 70% are positive. Northrop Grumman had 79 analyst reports since July 30, 2015 according to SRatingsIntel. The company was maintained on Thursday, July 30 by RBC Capital Markets. The stock of Northrop Grumman Corporation (NYSE:NOC) has “Hold” rating given on Monday, July 17 by Cowen & Co. The firm has “Buy” rating by RBC Capital Markets given on Sunday, October 8. Argus Research maintained the shares of NOC in report on Thursday, November 12 with “Buy” rating. Bernstein maintained Northrop Grumman Corporation (NYSE:NOC) on Thursday, April 26 with “Hold” rating. RBC Capital Markets maintained Northrop Grumman Corporation (NYSE:NOC) on Friday, January 29 with “Outperform” rating. The firm earned “Buy” rating on Friday, April 6 by RBC Capital Markets. Cowen & Co maintained it with “Market Perform” rating and $300 target in Thursday, October 26 report. On Friday, September 29 the stock rating was maintained by RBC Capital Markets with “Buy”. JP Morgan upgraded the shares of NOC in report on Wednesday, December 16 to “Overweight” rating.

Chilton Capital Management Llc, which manages about $1.18B and $1.21 billion US Long portfolio, decreased its stake in Avalonbay Cmntys Inc (NYSE:AVB) by 4,121 shares to 129,294 shares, valued at $23.42 million in 2018Q3, according to the filing. It also reduced its holding in Vanguard Scottsdale Fds (VCSH) by 7,081 shares in the quarter, leaving it with 20,054 shares, and cut its stake in Empire St Rlty Tr Inc (NYSE:ESRT).

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart